6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17–20 July 2011, Rome
The biannual IAS Conference on HIV Pathogenesis, Treatment and Prevention is more scientifically focused than the World AIDS Conference held in alternate years and is considerably smaller. This makes both attending and reporting more manageable and concentrated.
This year the conference was held in Rome. While plenary lectures were held in the concert halls designed by Renzo Piano (the architect designing the Shard Tower in London), smaller meetings were often in rooms with a capacity of only 50 people and the poster and exhibition halls were less than ideal, being held in the venues garages.
Even prior to the conference, the frenzy to gain media coverage filled email boxes with press releases that made it clear that the meeting would be dominated by prevention studies.
The leading prevention reports, first and most importantly, involved the reduction in transmission from use of HIV treatment for HIV-positive people. The risk is not reduced to zero, but it is getting close, especially when condoms remain the mainstay of prevention work. It means that if a condom breaks, slips off, or is not used at all, an HIV positive person who has had an undetectable viral load for over six months would find it difficult to transmit HIV.
The shift in medical consensus is dramatic. While the Swiss Statement three years ago was met with anger publically from many prominent doctors, in private most also recognised that viral load was the driving factor behind transmission risk. It was good to hear Pietro Vernazza who authored the Swiss paper ask Myron Cohen after presenting the results of HPTN 052 on whether Cohen’s new results had prompted a change of heart.
IAS in Rome included four oral presentations from the HPTN 052 study. Together they showed that HIV-positive people in high incidence resource limited settings (predominantly Africa, Asia and Latin America) who started treatment at a CD4 count of 350-550 reduced the risk of transmitting HIV to their HIV-negative primary partner by 96% compared to people waiting until their CD4 count was 250. This was a study that intensely integrated other prevention strategies – condom provision and counselling reduced transmission too, but treatment extended this significantly further.
The second way that treatment reduces transmission was supported by new studies reporting the benefits of PEP/PrEP strategies. These involved HIV negative people taking a daily pill of tenofovir/FTC, or tenofovir alone, which led to reductions in their risk of catching HIV.
As with previous meetings, the conference has an open-access searchable abstract database online.
However, many oral presentations are not included as webcasts or PowerPoint slides.
The ‘Programme at a glance’ can be searched for key words but requires a free software upgrade Silverlight which is quick and easy to do. Then from this page you can search abstracts or presentations.
Sessions with PowerPoint slides or webcasts have relevant icons next to them. As with previous years, the PowerPoint links on the left under the session time are not active, so to download PowerPoint files scroll down to the bottom of the session page
We have also included reports from the 3rd International Workshop on HIV Pediatrics immediately preceding IAS 2011. This small annual meeting is becoming quite established and although abstracts are often submitted to both meetings, in this one they may often get an oral presentation instead of just a poster. For those specialising in paediatrics this meeting is a welcome opportunity to present and discuss work in a dedicated forum. Abstracts and presentations are online. We have included references from both meetings in our paediatric reports.
Reports in this issue of HTB South include:
- Webcasts for major research at IAS
- Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred prior to viral suppression
- Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study
- Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP
- Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients
- Dolutegravir: 48 week results from phase II study in treatment-naïve patients
- Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naïve study
- SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression
- Hearing loss not associated with HIV in MACS and WIHS cohorts
- Pharmacokinetics of darunavir and fosamprenavir in pregnancy
- Low birth weight and preterm delivery
- Hormonal contraception and HIV transmission risk
- No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial
- Paediatric antiretroviral pipeline: update on etravirine and maraviroc
- More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study
- Prematurity not associated with early mortality in infants on ART
- Free online resource for treatment decisions without access to genotype resistance tests
Unless stated otherwise, all references are the Programme and Abstracts of the 16th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17–20 July 2011, Rome.